Skip to main content
OpenTrials
Completed

NCT Number: NCT01595958

Cyclosporine A in Cardiac Arrest

The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non Shockable Out of Hospital Cardiac Arrest Brain Diseases Brain Injuries Cardiovascular Diseases Central Nervous System Diseases Heart Arrest Heart Diseases Multiple Organ Failure Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Post-Cardiac Arrest Syndrome Postoperative Complications Reperfusion Injury Shock Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Medical intensive care unit, Edouard Herriot Hospital

Lyon, 69003, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Witnessed out-of-hospital cardiac arrest
  • Non shockable cardiac rhythm

Exclusion criteria

  • Evidence of trauma
  • Evidence of pregnancy
  • Duration of no flow more than 30 minutes
  • Rapidly fatal underlying disease
  • Allergy to cyclosporin A

Treatment and study plan

Cyclosporine A

Drug

Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation

cardio-pulmonary resuscitation

Procedure

usual care of cardiac arrest

Primary outcomes

  1. Sequential Organ Failure Assessment score (SOFA)

    Time frame: At 24 hours after hospital admission

Secondary outcomes

  1. Hospital admission with return of spontaneous circulation

    Time frame: At 24 hours following admission, at day 28, at hospital discharge (an average time frame of 7 days)

  2. Survival

    Time frame: At 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)

  3. Good cerebral outcome

    Time frame: At 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)

    Glasgow Coma Scale and Cerebral Performance Categories

  4. All adverse events

    Time frame: until hospital discharge (an average time frame of 7 days)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation

Acronym: CYRUS

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
May 10, 2012
Registry last updated
Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.